Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 0.68 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.55 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.55 |
| ▸ | RAF1 | P04049 | 1/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.55 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.55 |
| ▸ | LCK | P06239 | 3/20 | 0.54 |
| ▸ | KDR | P35968 | 3/20 | 0.54 |
| ▸ | KIT | P10721 | 2/20 | 0.54 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.47 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.47 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.47 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.47 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.47 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3536822 | 0.84 | MAPK14 (0.69) | MAPK14MAPKAPK2MAPK13RAF1PDGFRA | |
| SCHEMBL3820449 | 0.82 | MAPK14 (0.66) | MAPK14MAPKAPK2MAPK13RAF1PDGFRA | |
| SCHEMBL3534015 | 0.81 | MAPK14 (1.00) | MAPK14MAPKAPK2MAPK13RAF1PDGFRA | |
| SCHEMBL3667970 | 0.76 | MAPK14 (0.68) | MAPK14MAPKAPK2MAPK13RAF1PDGFRA | |
| SCHEMBL4738344 | 0.76 | RIPK2 (0.52) | MAPK14LCKRIPK2 | |
| SCHEMBL1313474 | 0.75 | MAPK14 (0.72) | MAPK14MAPKAPK2MAPK13RAF1PDGFRA | |
| SCHEMBL3535273 | 0.75 | RIPK2 (0.41) | MAPK14RIPK2 | |
| SCHEMBL1311133 | 0.73 | MAPK14 (0.69) | MAPK14MAPKAPK2MAPK13RAF1PDGFRA | |
| SCHEMBL1313093 | 0.73 | MAPK14 (0.68) | MAPK14MAPKAPK2MAPK13RAF1PDGFRA | |
| SCHEMBL3532368 | 0.73 | MAPK14 (0.86) | MAPK14MAPK11LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645764-B2 | Kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645764-B2 | Kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645764-B2 | Kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC (US) | 2010-01-12 | — | — | US | disclosed |
| CN-101535308-A | Substituted 6-phenyl-pyrido [2,3-D] pyrimidin-7-one derivatives as kinase inhibitors and methods for using the same | HOFFMANN LA ROCHE (CH) | 2009-09-16 | — | — | CN | disclosed |
| EP-2094698-A1 | SUBSTITUTED 6-PHENYL-PYRIDO [2,3-D]PYRIMIDIN-7-ONE DERIVATIVES AS KINASE INHIBITORS AND METHODS FOR USING THE SAME | F. Hoffmann-Roche AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| US-20080132528-A1 | Fused pyrimido-pyridone derivatives; to treat p38 MAP kinase-mediated and Raf kinase-mediated diseases; side effects reduction; broad spectrum antiproliferative agents; N-Cyclopropyl-4-methyl-3-[8-methyl-7-oxo-2-(tetrahydro-pyran-4-ylamino)-7,8-dihydro-pyrido[2,3-d]pyrimidin-6-yl]-benzamide | ROCHE PALO ALTO LLC | 2008-06-05 | — | — | US | disclosed |
| US-20080132528-A1 | Fused pyrimido-pyridone derivatives; to treat p38 MAP kinase-mediated and Raf kinase-mediated diseases; side effects reduction; broad spectrum antiproliferative agents; N-Cyclopropyl-4-methyl-3-[8-methyl-7-oxo-2-(tetrahydro-pyran-4-ylamino)-7,8-dihydro-pyrido[2,3-d]pyrimidin-6-yl]-benzamide | ROCHE PALO ALTO LLC | 2008-06-05 | — | — | US | disclosed |
| US-20080132528-A1 | Fused pyrimido-pyridone derivatives; to treat p38 MAP kinase-mediated and Raf kinase-mediated diseases; side effects reduction; broad spectrum antiproliferative agents; N-Cyclopropyl-4-methyl-3-[8-methyl-7-oxo-2-(tetrahydro-pyran-4-ylamino)-7,8-dihydro-pyrido[2,3-d]pyrimidin-6-yl]-benzamide | ROCHE PALO ALTO LLC | 2008-06-05 | — | — | US | disclosed |
| WO-2008055842-A1 | SUBSTITUTED 6-PHENYL-PYRIDO [2,3-D] PYRIMIDIN-7-ONE DERIVATIVES AS KINASE INHIBITORS AND METHODS FOR USING THE SAME | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132528-A1 | Fused pyrimido-pyridone derivatives; to treat p38 MAP kinase-mediated and Raf kinase-mediated diseases; side effects reduction; broad spectrum antiproliferative agents; N-Cyclopropyl-4-methyl-3-[8-methyl-7-oxo-2-(tetrahydro-pyran-4-ylamino)-7,8-dihydro-pyrido[2,3-d]pyrimidin-6-yl]-benzamide | MAP3K6, MAP3K1, MAP3K2 | MAPK14 44/4885MAPKAPK2 22/4885MAPK13 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.